Suppr超能文献

不同的新冠病毒疫苗对不同病毒变种的防护效果如何?一项系统评价与荟萃分析。

How well do different COVID-19 vaccines protect against different viral variants? A systematic review and meta-analysis.

作者信息

Hoang Thi Ngoc Anh, Byrne Aisling, Quach Ha-Linh, Bannister-Tyrrell Melanie, Vogt Florian

机构信息

Faculty of Public Health, PHENIKAA University, Yen Nghia, Ha Dong, Hanoi 12116, Vietnam.

National Centre for Epidemiology and Population Health, Research School of Population Health, College of Health and Medicine, Australian National University, Canberra, ACT 2601, Australia.

出版信息

Trans R Soc Trop Med Hyg. 2025 Jan 3;119(1):1-12. doi: 10.1093/trstmh/trae082.

Abstract

While the efficacy of coronavirus disease 2019 (COVID-19) vaccines has been evaluated in numerous trials, comprehensive evidence on how protection by different vaccines has varied over time remains limited. We aimed to compare protective effects of different vaccines against different viral variants. To achieve this, we searched Medline, Cochrane Library and Embase for randomized controlled trials assessing the efficacy of COVID-19 vaccines. Forest plots using Mantel-Haenszel and random-effects models were generated showing risk ratios (RRs) and 95% CIs by vaccines and variants. We included 36 studies with 90 variant-specific primary outcomes. We found a RR of 0.26 (95% CI 0.21 to 0.31) against all variants overall, with the highest protective effects against the wild-type (RR 0.13; 95% CI 0.10 to 0.18), followed by Alpha (RR 0.26; 95% CI 0.18 to 0.36), Gamma (RR 0.34; 95% CI 0.21 to 0.55), Delta (RR 0.39; 95% CI 0.28 to 0.56) and Beta (RR 0.49; 95% CI 0.40 to 0.62) variants. Nucleic acid vaccines showed the highest protection levels against all variants (RR 0.11; 95% CI 0.08 to 0.15), followed by protein subunit, inactivated virus and viral vector. In conclusion, we found high but heterogenous levels of protection for most COVID-19 vaccines, with decreasing protective effects for vaccines based on traditional technologies as SARS-CoV-2 variants emerged over time. Novel nucleic acid-based vaccines offered substantially higher and more consistent protection.

摘要

虽然2019冠状病毒病(COVID-19)疫苗的疗效已在众多试验中得到评估,但关于不同疫苗的保护效果如何随时间变化的全面证据仍然有限。我们旨在比较不同疫苗对不同病毒变体的保护作用。为实现这一目标,我们在Medline、Cochrane图书馆和Embase中检索了评估COVID-19疫苗疗效的随机对照试验。使用Mantel-Haenszel和随机效应模型生成森林图,显示不同疫苗和变体的风险比(RR)及95%置信区间(CI)。我们纳入了36项研究,共有90个变体特异性主要结局。我们发现,总体而言,针对所有变体的RR为0.26(95%CI为0.21至0.31),对野生型的保护效果最高(RR为0.13;95%CI为0.10至0.18),其次是Alpha变体(RR为0.26;95%CI为0.18至0.36)、Gamma变体(RR为0.34;95%CI为0.21至0.55)、Delta变体(RR为0.39;95%CI为0.28至0.56)和Beta变体(RR为0.49;95%CI为0.40至0.62)。核酸疫苗对所有变体的保护水平最高(RR为0.11;95%CI为0.08至0.15),其次是蛋白亚单位疫苗、灭活病毒疫苗和病毒载体疫苗。总之,我们发现大多数COVID-19疫苗的保护水平较高但存在异质性,随着时间推移,随着严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体的出现,基于传统技术的疫苗保护效果逐渐降低。新型核酸疫苗提供了更高且更一致的保护。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2dd6/11697103/67de523bd6d8/trae082fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验